Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
0.5600 x 18 0.5650 x 4
Post-market by (Cboe BZX)
0.5562 -0.0271 (-4.65%) 04/25/25 [NASDAQ]
0.5600 x 18 0.5650 x 4
Post-market 0.5650 +0.0088 (+1.58%) 19:42 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.5451
Day High
0.5900
Open 0.5900
Previous Close 0.5833 0.5833
Volume 288,400 288,400
Avg Vol 374,640 374,640
Stochastic %K 55.15% 55.15%
Weighted Alpha -59.06 -59.06
5-Day Change -0.0048 (-0.86%) -0.0048 (-0.86%)
52-Week Range 0.4679 - 1.5300 0.4679 - 1.5300
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,410
  • Shares Outstanding, K 86,422
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,140 K
  • EBIT $ -26 M
  • EBITDA $ -25 M
  • 60-Month Beta 1.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.39
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.30
  • Most Recent Earnings $-0.07 on 03/07/25
  • Next Earnings Date 05/08/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.09
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4679 +18.87%
on 04/04/25
Period Open: 0.6347
0.6500 -14.43%
on 04/11/25
-0.0785 (-12.37%)
since 03/25/25
3-Month
0.4679 +18.87%
on 04/04/25
Period Open: 0.7874
0.8400 -33.79%
on 02/06/25
-0.2312 (-29.36%)
since 01/24/25
52-Week
0.4679 +18.87%
on 04/04/25
Period Open: 1.0800
1.5300 -63.65%
on 10/07/24
-0.5238 (-48.50%)
since 04/25/24

Most Recent Stories

More News
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data...

ONCY : 0.5562 (-4.65%)
ONC.TO : 0.77 (-4.94%)
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

/CNW/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable...

ONCY : 0.5562 (-4.65%)
ONC : 244.90 (-4.40%)
CVM : 0.2904 (-2.06%)
ONC.TO : 0.77 (-4.94%)
ATNM : 1.3100 (+3.15%)
OSTX : 1.6000 (-0.62%)
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Routine medical appointments or cancer screening rates—an important aspect in increasing survival...

ONCY : 0.5562 (-4.65%)
URGN : 9.87 (-2.37%)
NVS : 112.14 (+0.87%)
PHIO : 2.04 (-8.52%)
ONC.TO : 0.77 (-4.94%)
HURA : 4.10 (-3.07%)
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a...

ONCY : 0.5562 (-4.65%)
ONC.TO : 0.77 (-4.94%)
Private Sector Steps Up in Cancer Research as Federal Support Wavers

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As the Trump administration signals potential cuts to the National Institutes of Health (NIH), questions...

ONCY : 0.5562 (-4.65%)
SMMT : 23.47 (-36.06%)
CADL : 4.98 (-0.40%)
IMTX : 4.52 (-3.21%)
EXEL : 37.43 (+0.59%)
ONC.TO : 0.77 (-4.94%)
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by...

ONCY : 0.5562 (-4.65%)
ONC.TO : 0.77 (-4.94%)
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

/CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...

ONCY : 0.5562 (-4.65%)
EXEL : 37.43 (+0.59%)
ONC.TO : 0.77 (-4.94%)
ALXO : 0.5417 (-9.87%)
CRDF : 2.88 (-0.69%)
VSTM : 7.50 (unch)
Stocks in play: Oncolytics Biotech Inc

Announces reporting on highlights and financial results for Q4 and year-end 2024. With its lead candidate, ...

ONCY : 0.5562 (-4.65%)
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never been more...

ALLO : 1.5500 (-1.27%)
ONCY : 0.5562 (-4.65%)
TARA : 4.32 (+5.11%)
YMAB : 4.10 (-0.73%)
FATE : 1.2800 (-5.19%)
ONC.TO : 0.77 (-4.94%)
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on...

ONCY : 0.5562 (-4.65%)
ONC.TO : 0.77 (-4.94%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 0.6273
2nd Resistance Point 0.6087
1st Resistance Point 0.5824
Last Price 0.5562
1st Support Level 0.5375
2nd Support Level 0.5189
3rd Support Level 0.4926

See More

52-Week High 1.5300
Fibonacci 61.8% 1.1243
Fibonacci 50% 0.9990
Fibonacci 38.2% 0.8736
Last Price 0.5562
52-Week Low 0.4679

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective